Clinical Trial Update: Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the AKT inhibitor GSK690693 in relapsed or refractory hematologic malignancies has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• GSK690693

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: WITHDRAWN